Epitome Biosystems Completes Development of Multiplex Assays for EMD Biosciences Inc.

Epitome Biosystems

Epitome Biosystems Completes Development of Multiplex Assays for EMD Biosciences Inc.

January 31, 2007

Waltham, MA, and Madison, WI, January 31, 2007 – Epitome Biosystems and EMD Biosciences Inc. announced today the successful completion of a collaboration to develop multiplex assays to measure phosphorylation of cell signaling proteins using Epitome’s EpiTag™ technology. Epitome developed custom antibody and peptide reagents to enable quantitative protein measurements of selected targets for EMD Biosciences. This completes the first commercial partnership for Epitome. Products resulting from this collaboration will be manufactured, marketed and sold for research applications on a world-wide basis by EMD Biosciences Inc. through its Novagen brand.

“Achieving this important product development milestone serves as further validation for our EpiTag™ technology platform and, importantly, will lead to the imminent commercial launch of products,” said Neal Gordon, Ph.D., President, Epitome Biosystems. “These efforts are contributing to our goal of generating a comprehensive product suite to assess biological function with numerous applications in drug discovery and development.”

“The EpiTag™ technology facilitates the rapid development of robust multiplex immunoassays, including those that can interrogate novel phosphorylated targets” said Graham Scott, Ph.D., Senior Director (Biodiscovery) of EMD Biosciences Inc. “This joint development project with Epitome has clearly demonstrated the considerable power and utility of this platform technology, and we are excited about commercializing these innovative assays.”

Epitome’s proprietary EpiTag™ technology enables the reliable and cost-effective development of assays for the quantitative measurement of proteins in “sandwich” assay formats. The flexible technology has been applied to develop antibody array products for broad profiling of intracellular signaling and products for highly quantitative protein measurements in multiplex formats. The phosphorylation state of intracellular signaling proteins is an important indicator of biological function and is useful in the characterization of disease. Although sandwich antibody pairs provide highly specific and sensitive protein measurements, they are difficult to develop and limited in availability. Epitome’s approach overcomes these limitations and facilitates rapid assay development and targeting of novel measurements.

About Epitome Biosystems

Epitome Biosystems is applying its protein measurement system to increase the productivity of drug discovery and development and improve the understanding of patient variability and disease. The Company’s EpiTag™ technology delivers highly specific, quantitative measurements of any protein or proteins in a user-friendly format. Epitome’s technology is validated, scaleable and can be applied broadly to assessing protein functional states and activities, including phosphorylation. For more information, visit www.epitomebiosystems.com.

About EMD Biosciences, Inc.

EMD Biosciences, Inc. provides a broad range of innovative life science research products used world-wide in disease-related life science research at universities as well as in the pharmaceutical and biotech industries. The company is part of the Performance and Life Science Chemicals (PLS) division of Merck KGaA, Darmstadt, Germany and operates as EMD Biosciences, Inc. in North America and Merck Biosciences outside North America. Globally, EMD Biosciences is known in the scientific community through its product brands Calbiochem®, Novabiochem®, and Novagen®.

About Merck KGaA, Darmstadt, Germany

Merck is a global pharmaceutical and chemical company with sales of EUR 6.3 billion in 2006, a history that began in 1668, and a future shaped by about 35,000 employees (including Merck Serono) in 56 countries. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.


Neal F. Gordon, Ph.D.
Epitome Biosystems
(781) 891-3816

Graham Scott, Ph.D.
Senior Director Biodiscovery
EMD Biosciences Inc
(608) 442-4027